Sfoglia per Autore
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase
2022 Mologni, L; Tardy, S; Zambon, A; Orsato, A; Bisson, W; Ceccon, M; Viltadi, M; D'Attoma, J; Pannilunghi, S; Vece, V; Bertho, J; Goekjian, P; Scapozza, L; Gambacorti-Passerini, C
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase
2022 Mologni, L; Orsato, A; Zambon, A; Tardy, S; Bisson, W; Schneider, C; Ceccon, M; Viltadi, M; D'Attoma, J; Pannilunghi, S; Vece, V; Gueyrard, D; Bertho, J; Scapozza, L; Goekjian, P; Gambacorti-Passerini, C
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models
2021 Sharma, G; Arosio, G; Villa, M; Mauri, M; Zappa, M; Magistroni, V; Ceccon, M; Redaelli, S; Crespiatico, I; Fontana, D; Mastini, C; Garbin, A; Lovisa, F; Mussolin, L; Piazza, R; Gambacorti Passerini, C; Mologni, L
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma
2021 Arosio, G; Sharma, G; Villa, M; Mauri, M; Crespiatico, I; Fontana, D; Manfroni, C; Mastini, C; Zappa, M; Magistroni, V; Ceccon, M; Redaelli, S; Massimino, L; Garbin, A; Lovisa, F; Mussolin, L; Piazza, R; Gambacorti Passerini, C; Mologni, L
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target
2021 Larose, H; Prokoph, N; Matthews, J; Schlederer, M; Hogler, S; Alsulami, A; Ducray, S; Nuglozeh, E; Fazaludeen, M; Elmouna, A; Ceccon, M; Mologni, L; Gambacorti Passerini, C; Hoefler, G; Lobello, C; Pospisilova, S; Janikova, A; Woessmann, W; Damm-Welk, C; Zimmermann, M; Fedorova, A; Malone, A; Smith, O; Wasik, M; Inghirami, G; Lamant, L; Blundell, T; Klapper, W; Merkel, O; Amos Burke, G; Mian, S; Ashankyty, I; Kenner, L; Turner, S
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers
2018 Geeta, G; Redaelli, S; Ceccon, M; Zappa, M; Gambacorti-Passerini, C; Mologni, L
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling
2018 Ceccon, M; Mauri, M; Massimino, L; Giudici, G; Piazza, R; Gambacorti-Passerini, C; Mologni, L
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer
2018 Redaelli, S; Ceccon, M; Zappa, M; Geeta, G; Mastini, C; Mauri, M; Nigoghossian, M; Massimino, L; Cordani, N; Farina, F; Piazza, R; Gambacorti-Passerini, C; Mologni, L
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates
2017 Farina, F; Ceccon, M; Mori, S; Verga, L; Borin, L; Mologni, L; Fontana, D; Geeta, G; Piazza, R; Gambacorti-Passerini, C
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
2016 Redaelli, S; Ceccon, M; Antolini, L; Rigolio, R; Pirola, A; Peronaci, M; GAMBACORTI PASSERINI, C; Mologni, L
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency
2016 Ceccon, M; Merlo, M; Mologni, L; Poggio, T; Varesio, L; Menotti, M; Bombelli, S; Rigolio, R; Manazza, A; Di Giacomo, F; Ambrogio, C; Giudici, G; Casati, C; Mastini, C; Compagno, M; Turner, S; GAMBACORTI PASSERINI, C; Chiarle, R; Voena, C
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma
2015 Redaelli, S; Ceccon, M; Pirola, A; Peronaci, M; Gambacorti-Passerini, C; Mologni, L
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
2015 Mologni, L; Ceccon, M; Pirola, A; Chiriano, G; Piazza, R; Scapozza, L; GAMBACORTI PASSERINI, C
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
2015 Fontana, D; Ceccon, M; GAMBACORTI PASSERINI, C; Mologni, L
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors
2015 Mologni, L; Ceccon, M; Fontana, D; Pirola, A; Piazza, R; Gambacorti-Passerini, C
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783))
2015 Ceccon, M; Mologni, L; Giudici, G; Piazza, R; Pirola, A; Fontana, D
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth
2015 Hoareau Aveilla, C; Valentin, T; Daugrois, C; Quelen, C; Mitou, G; Quentin, S; Jia, J; Spicuglia, S; Ferrier, P; Ceccon, M; Giuriato, S; GAMBACORTI PASSERINI, C; Brousset, P; Lamant, L; Meggetto, F
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma
2015 Ceccon, M; Mologni, L; Giudici, G; Piazza, R; Pirola, A; Fontana, D; GAMBACORTI PASSERINI, C
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib
2015 Redaelli, S; Perini, P; Ceccon, M; Piazza, R; Rigolio, R; Mauri, M; Boschelli, F; Giannoudis, A; GAMBACORTI PASSERINI, C
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency
2015 Ceccon, M; Boggio Merlo, M; Mologni, L; Varesio, L; Poggio, T; Menotti, M; Bombelli, S; Rigolio, R; Manazza, A; Ambrogio, C; Giudici, G; Casati, C; Compagno, M; Turner, S; Gambacorti Passerini, C; Chiarle, R; Voena, C
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile